Son-Of-Xigris Goes to Biotech--Where it Belongs?

When Eli Lilly licensed the follow-on drug candidate to sepsis treatment Xigris to Cardiome, it was a tacit acknowledgment that this family of specialist products may be better suited to biotech. Perhaps they should have done the same with Xigris.